[(5R)-8-propan-2-yl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: [(5R)-8-propan-2-yl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
• 化学式: C₁₉H₂₇NO₃
• 分子量: 317.4
• InChiKey: VORSMCHHJRVORT-VGZZGSPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• INHALABLE MEDICAMENT
  申请人：Teva Branded Pharmaceutical Products R&D, Inc.

  公开号：US20160243241A1

  公开（公告）日：2016-08-25

  The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.
• AN INHALABLE MEDICAMENT
  申请人：Teva Branded Pharmaceutical Products R&D, Inc.

  公开号：US20160250197A1

  公开（公告）日：2016-09-01

  Accordingly, the present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.
• US9707295B2
  申请人：——

  公开号：US9707295B2

  公开（公告）日：2017-07-18
• [EN] INHALATION COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST<br/>[FR] COMPOSITIONS D'INHALATION COMPRENANT UN ANTAGONISTE DU RÉCEPTEUR MUSCARINIQUE
  申请人：SANOVEL ILAC SANAYI VE TICARET

  公开号：WO2014007771A2

  公开（公告）日：2014-01-09

  The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.
• [EN] AN INHALABLE MEDICAMENT<br/>[FR] MÉDICAMENT INHALABLE
  申请人：TEVA BRANDED PHARMACEUTICAL PROD R & D INC

  公开号：WO2015077574A1

  公开（公告）日：2015-05-28

  The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.